Thomas Stricker, Neha Jain, Esprit Ma, Elaine Yu, Rongrong Wang, Robert Schuldt, Richard Price, Tania Szado, Jesse Sussell, Sarika Ogale, Victor Lin, Edward Arrowsmith, Dennis Slater, Daniel Vaena, Harry Staszewski, Bruno Fang, Lasika Seneviratne, Davey Daniel
BACKGROUND: A recent real-world study observed that 24% of patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADOs) initiated nontargeted therapies before biomarker test results became available. This study assessed the clinical impact of the timing of first-line (1L) targeted therapies (TTs) in aNSCLC. MATERIALS AND METHODS: This retrospective analysis of a nationwide electronic health record-derived deidentified database included patients aged ≥18 years diagnosed with aNSCLC with ADOs (ALK, BRAF, EGFR, RET, MET, ROS-1, and NTRK) from January 1, 2015, to October 18, 2022, by biomarker testing within 90 days after advanced diagnosis and received 1L treatment...
February 28, 2024: Oncologist